HPV vaccine: knowledge and acceptance to ensure effectiveness

Autores

  • Isabel Cristina Esposito Sorpreso Disciplina de Ginecologia. Departamento de Obstetrícia e Ginecologia da Faculdade de Medicina da Universidade de São Paulo
  • Patricia Jane Kelly School of Nursing. University of Missouri

DOI:

https://doi.org/10.7322/jhgd.143887

Palavras-chave:

HPV, papillomavirus vaccines, human papillomavirus recombinant vaccine quadrivalent, types 6, 11, 16, 18, uterine cervical neoplasms

Resumo

The new Vaccine technologies against transmissible and non-transmissible diseases, such as cancer, have had an impact on international public health. The human papillomavirus (HPV) vaccine is used on a large scale in immunization programs in more than 58 countries, with resultant efficacy and safety for precursor lesions of cervical cancer, in addition to anogenital lesions. After the introduction of quadrivalent HPV vaccine (6,11,16 and 18) in Brazil in 2014, monitoring the vaccination coverage and the development of HPV prevalence incidence of cervical abnormalities and precancerous lesions must be observed, as well as morbidity and mortality trends from in situ and invasive cancer. Encouraging information, counseling and continuing education is recommended as a strategy to broaden vaccine acceptance in order to sediment its implementation and ensure effectiveness in reducing new cases of cervical cancer in the future.

Downloads

Os dados de download ainda não estão disponíveis.

Referências

McGuire S. World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. Adv Nutr. 2016;7(2):418-9. DOI: http://dx.doi.org/10.3945/an.116.012211

Nascimento MDDSB, Vidal FCB, Silva MACND, Batista JE, Barbosa MDCL, Muniz Filho WE, et al. Prevalence of human papillomavirus infection among women from quilombo communities in northeastern Brazil. BMC Women’s Health. 2018;18(1):1. DOI: http://dx.doi.org/10.1186/s12905-017-0499-3

Castle PE, Maza M. Prophylactic HPV vaccination: past, present, and future. Epidemiol Infect. 2016;144(3):449-68. DOI: http://dx.doi.org/10.1017/S0950268815002198

Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356(19):1928-43. DOI: http://dx.doi.org/10.1056/NEJMoa061760

The Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356(19):1915-27. DOI: http://dx.doi.org/10.1056/NEJMoa061741

Markowitz LE, Dunne EF, Saraiya M, Chesson HW, Curtis CR, Gee J, et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2014;63(RR-05):1-30.

Human papillomavirus vaccines. WHO position paper. Wkly Epidemiol Rec. 2009;84(15):118-31.

Ferrer HB, Trotter C, Hickman M, Audrey S. Barriers and facilitators to HPV vaccination of young women in high-income countries: a qualitative systematic review and evidence synthesis. BMC Public Health. 2014;14:700. DOI: http://dx.doi.org/10.1186/1471-2458-14-700

Novaes HM, Soárez PC, Silva GA, Ayres A, Itria A, Rama CH, et al. Cost-effectiveness analysis of introducing universal human papillomavirus vaccination of girls aged 11 years into the National Immunization Program in Brazil. Vaccine. 2015;33(Suppl 1):A135-42. DOI: http://dx.doi.org/10.1016/j.vaccine.2014.12.031

Perkins RB, Brogly SB, Adams WG, Freund KM. Correlates of human papillomavirus vaccination rates in low-income, minority adolescents: a multicenter study. J Womens Health. 2012;21(8):813-20. DOI: http://dx.doi.org/10.1089/jwh.2011.3364

Bynum SA, Staras SA, Malo TL, Giuliano AR, Shenkman E, Vadaparampil ST. Factors Associated with Medicaid Providers Recommendation of the HPV Vaccine to Low-Income Adolescent Girls. J Adolesc Health. 2014;54(2):190-6. DOI: http://dx.doi.org/10.1016/j.jadohealth.2013.08.006

Sousa PDL, Sorpreso ICE, Takiuti AD, Abreu LC. Knowledge and acceptance of HPV vaccine among adolescents, parents and health professionals: construct development for collection and data base composition. J Hum Growth Dev. 2018; 28(1):58-68. DOI: http://dx.doi.org/10.7322/jhgd.143856

Melo RMSB, Morais GB, Morais JB, Leite SN. Conception of the Right to Health of Mid-Level Technical Professionals of Unified Health System In Brazil. J Hum Growth Dev. 2018; 28(1):95-104. DOI: http://dx.doi.org/10.7322/jhgd.143886

Leite JC, Neves JCJ, Vitor LGV, Fujisawa DS. Evaluation of postural control in children and adolescents with Down Syndrome aged eight to twelve years old. J Hum Growth Dev. 2018; 28(1):50-7. DOI: http://dx.doi.org/10.7322/jhgd.127335

Bessa ARS, Dotto LMG, Cunha MA, Muniz PT, Koifman S, Cavalcante SO. Delivery and postpartum care in Rio Branco in the northern state of Acre, Brazil: a populationbased survey. J Hum Growth Dev. 2018; 28(1):69-76. DOI: http://dx.doi.org/10.7322/jhgd.118010

Rigo L, Cericato GO, Sabadin CS, Solda C, Mário DN, Buzalaf MAR. Fingernails as a biomarker for dental fluorosis. J Hum Growth Dev. 2018; 28(1):82-8. DOI: http://dx.doi.org/10.7322/jhgd.133582

Lima RE, Aleixo AA, Araújo LB, Nascimento CP, Azevedo VMGO. Neuropsychomotor development characteristics of the infants who born from women who abused drugs during pregnancy. J Hum Growth Dev. 2018; 28(1): 27-34. DOI: http://dx.doi.org/10.7322/jhgd.134374

Guedes-Granzotti RB, Siqueira LS, Cesar CPHAR, Silva K, Domenis DR, Dornelas R, et al. Neuropsychomotor development and auditory skills in preschool children. J Hum Growth Dev. 2018; 28(1):35-41. DOI: http://dx.doi.org/10.7322/jhgd.123380

Pinto VCM, Santos PGMD, Medeiros RCSC, Souza FES, Simões TBS, Dantas RPNC, et al. Maturational stages: comparison of growth and physical capacity indicators in adolescentes. J Hum Growth Dev. 2018; 28(1):42-9. DOI: http://dx.doi.org/10.7322/jhgd.127411

Barreto GMS, Balbo SL, Rover MS, Toso BRGO, Oliveira HR, Viera CS. Growth and biochemical markers of newborn preterm up to six months of corrected age. J Hum Growth Dev. 2018; 28(1):18-26. DOI: http://dx.doi.org/10.7322/jhgd.138687

Prata ARS, Pedroso D, Menezes G, Drezett J, Torres JHR, Bonfim JRA, et al. Juridical perspectives of interruption of pregnancy with zika virus infection regarding medical, emotional and social consequences. J Hum Growth Dev. 2018; 28(1): 77-81. DOI: http://dx.doi.org/10.7322/jhgd.143875

Almeida RC, Zachêu PRZ, Diniz MT, Dias MCCPO, Guiguer IC, Almeida RC, Corrêa JA. Portuguese translation and Brazilian cultural adaptation of the Assessment of Burden in Chronic Venous Disease questionnaire (ABC-V) . J Hum Growth Dev. 2018; 28(1):89-94. DOI: http://dx.doi.org/10.7322/jhgd.143885

Okasaki R, Carvalho WB, Ceccon MEJR. Newborns with staphylococcus aureus and coagulase-negative sepsis treated with vancomycin after an increase in serum levels in the voucher. J Hum Growth Dev. 2018; 28(1):9-17. DOI: http://dx.doi.org/10.7322/jhgd.143846

Downloads

Publicado

2018-03-12

Edição

v. 28 n. 1 (2018)

Seção

Editorial

Licença

CODE OF CONDUCT FOR JOURNAL  PUBLISHERS

 

Publishers who are Committee on Publication Ethics members and who support COPE membership for journal editors should:

 

Publishers should:

 

  • Define the relationship between publisher, editor and other parties in a contract
  • Respect privacy (for example, for research participants, for authors, for peer reviewers)
  • Protect intellectual property and copyright
  • Foster editorial independence

 

Publishers should work with journal editors to:

 

  • Set journal policies appropriately and aim to meet those policies, particularly with respect to:

–         Editorial  independence

–         Research ethics, including confidentiality, consent, and the special requirements for human and animal research

–         Authorship

–         Transparency and integrity (for example, conflicts of interest, research funding, reporting standards

–         Peer review and the role of the editorial team beyond that of the journal editor

–         Appeals and complaints

  • Communicate journal policies (for example, to authors, readers, peer reviewers)
  • Review journal policies periodically, particularly with respect to new recommendations from the COPE
  • Code of Conduct for Editors and the COPE Best Practice Guidelines
  • Maintain the integrity of the academic record
  • Assist the parties (for example, institutions, grant funders, governing bodies) responsible for the investigation of suspected research and publication misconduct and, where possible, facilitate in the resolution of these cases
  • Publish corrections, clarifications, and retractions
  • Publish content on a timely basis